Related Experiment Videos
[Breast cancer in advanced age]
A Gentile1, L Greco, C Chiumarulo
1Dipartimento d'Odontoiatria e Chirurgia, Sezione di Chirurgia Generale, Università degli Studi di Bari.
Annali Italiani Di Chirurgia
|December 18, 2003
Summary
Older adults with breast carcinoma can often tolerate standard treatments, including chemotherapy, similar to younger patients. Treatment decisions should focus on biological age and patient health, not just chronological age.
Area of Science:
- Oncology
- Geriatric Medicine
- Clinical Research
Context:
- Breast carcinoma incidence rises with age, posing a growing challenge due to population aging.
- Elderly patients are frequently undertreated for breast cancer based on misconceptions about their tolerance to standard therapies.
- There is a lack of scientific evidence supporting the exclusion of older adults from aggressive breast cancer treatment regimens.
Purpose:
- To challenge the prevailing prejudice against administering standard multimodal therapy to elderly breast carcinoma patients.
- To advocate for treatment decisions in older patients that are comparable to those for younger individuals.
- To emphasize the importance of considering biological age over chronological age in therapeutic choices.
Summary:
- Breast carcinoma treatment for elderly patients should not be limited by age; standard multimodal therapies, including chemotherapy, are often well-tolerated.
- Studies indicate that side effects in elderly patients undergoing chemotherapy are comparable to those in younger cohorts.
- Treatment should be individualized, considering biological age, life expectancy, and patient expectations, with conservative approaches reserved for the particularly frail.
Impact:
- Promotes evidence-based treatment strategies for elderly breast cancer patients, potentially improving outcomes.
- Challenges ageist biases in clinical practice, encouraging more equitable care.
- Highlights the need for personalized medicine in oncology, moving beyond chronological age as a primary determinant for treatment eligibility.